Drug intelligence / Profile preview

ELI-501

Development stage: Preclinical
Lead developer: Eli Radiopharma
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ELI-501 is a discovery-stage radiopharmaceutical candidate being developed by Eli Radiopharma. It is designed as a theranostic agent, a dual-purpose molecule that can be labeled with Gallium-68 (⁶⁸Ga) for diagnostic positron emission tomography (PET) imaging or Lutetium-177 (¹⁷⁷Lu) for targeted radionuclide therapy. This theranostic approach allows for the identification of patients who express the drug's target via imaging before administering the therapeutic dose. As of 2024, the specific molecular target and the primary disease indications for ELI-501 remain undisclosed by the sponsor.

Beyond the preview

Go deeper on ELI-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELI-501.

Explore the full profile